Evernorth — the Cigna division that oversees ... that can help employers cap the monthly copays for two popular weight-loss drugs, Wegovy and Zepbound, at $200. The impact on the employers ...

Getting access to popular weight loss drugs will be simpler and cheaper for some.Health insurer Cigna (CI) announced a new deal for copay caps on Eli Lilly (LLY) and Novo Nordisk (NVO) weight loss ...

The Cigna unit positioned the initiative as a cheaper alternative to cash-pay programs. Wegovy maker Novo Nordisk and Zepbound manufacturer Eli Lilly directly sell their drugs to certain patients ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...

Only half of health insurer Cigna's clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company's pharmacy benefits unit Evernorth ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Evernorth, the pharmacy benefits unit for health insurer giant Cigna, has reached ... patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200.

Last month, CVS Caremark announced that it had struck a deal to make Novo's Wegovy its primary weight ... help people with obesity access Zepbound." While Cigna would not discuss the actual ...

The Cigna Group (NYSE:CI)'s Evernorth division ... customers' monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200. A healthcare team discussing strategies for patient ...